- 英文名称
- Danoprevir
- 分子式
- C35H46FN5O9S
- 分子量
- 731.83
- 中文别名
- 丹诺瑞韦; RG7227; ITMN-191; RO5190591; (2R,6S,13AS,14AR,16AS,Z)-6-((叔丁氧羰基)氨基)-14A-((环丙基磺酰基)氨基甲酰基)-5,16-二氧代-1,2,3,5,6,7,8,9,10,11,13A,14,14A,15,16,16A-十六氢环丙[E]吡咯并[1,2-A][1,4]二氮杂环十五-2-基 4-氟异吲哚啉-2-甲酸酯; RG7227; ITMN-191; RO5190591; 4-Fluoro-1,3-dihydro-2H-isoindole-2-carboxylic acid (2R,6S,13aS,14aR,16aS)-14a-[[(cyclopropylsulfonyl)amino]carbonyl]-6-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl ester; (2R,6S,12Z,13aS,14aR,16aS)-14a-[(Cyclopropylsulfonyl)carbamoyl]-6-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoro-1,3-dihydro-2H-isoindole-2-carboxylate
- 用途
- 作为HCV NS3/4A蛋白酶抑制剂,抑制HCV复制,对HCV 1A/1B/4/5/6基因型效果显著,Phase 2临床研究阶段,体外和体内实验显示其高活性和特异性。